Evidence map›Paper›PMID 40877637›Full record

ArticleBritish journal of cancer2025

Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.

Anwar Mulugeta, David Stacey, Amanda L Lumsden, Iqbal Madakkatel, S Hong Lee, Johanna Mäenpää, Martin K Oehler, Elina Hyppönen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anwar MulugetaAustralian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia. anwarmulugeta.gebremichael@unisa.edu.au.ORCID http://orcid.org/0000-0002-8018-3454
David StaceyAustralian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-9392-9235
Amanda L LumsdenAustralian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Iqbal MadakkatelAustralian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
S Hong LeeAustralian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Johanna MäenpääFaculty of Medicine and Medical Technology, Tampere University, Tampere, Finland.
Martin K OehlerDepartment of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Elina HyppönenAustralian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer (OC) is often diagnosed at an advanced stage when prognosis is poor. We aimed to identify blood plasma proteins predictive of OC risk.

methodsWe conducted proteome-wide Mendelian randomisation (MR) analyses using summary-level protein quantitative trait locus data covering 2337 plasma proteins, and genome-wide association data on OC and its subtypes (up to 25,509 cases) from the Ovarian Cancer Association Consortium. Wald ratio or inverse-variance weighted MR analysis was used as the primary method, depending on the number of instruments. We evaluated pleiotropy using MR-Egger intercept test and leave-one-out analysis.

resultsFrom 2337 plasma proteins, 12 were associated (p < 7.4 × 10

conclusionOur study suggests FSHB and 11 additional plasma proteins as of potential interest in OC (or subtypes) prognosis, mostly representing potentially druggable targets.

Indexed as

Biomarkers, TumorBlood ProteinsOvarian NeoplasmsProteomeFemaleGenome-Wide Association StudyHumansMendelian Randomization AnalysisPolymorphism, Single NucleotidePrognosisQuantitative Trait LociBiomarkers, TumorBlood ProteinsProteome

Identifiers

PMID40877637
PMCPMC12532995

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.